U.S. markets closed
  • S&P 500

    4,422.30
    +10.51 (+0.24%)
     
  • Dow 30

    35,144.31
    +82.76 (+0.24%)
     
  • Nasdaq

    14,840.71
    +3.72 (+0.03%)
     
  • Russell 2000

    2,216.92
    +7.27 (+0.33%)
     
  • Crude Oil

    72.18
    +0.11 (+0.15%)
     
  • Gold

    1,797.40
    -4.40 (-0.24%)
     
  • Silver

    25.25
    +0.01 (+0.05%)
     
  • EUR/USD

    1.1805
    +0.0035 (+0.30%)
     
  • 10-Yr Bond

    1.2760
    -0.0100 (-0.78%)
     
  • GBP/USD

    1.3822
    +0.0068 (+0.49%)
     
  • USD/JPY

    110.3640
    -0.1460 (-0.13%)
     
  • BTC-USD

    37,693.12
    +3,252.82 (+9.44%)
     
  • CMC Crypto 200

    905.01
    -10.48 (-1.14%)
     
  • FTSE 100

    7,025.43
    -2.15 (-0.03%)
     
  • Nikkei 225

    27,833.29
    +285.29 (+1.04%)
     

Evofem Biosciences to Present at Jefferies Virtual Healthcare Conference 2021

·1 min read

SAN DIEGO, June 1, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Saundra Pelletier, Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference 2021 as follows:

(PRNewsfoto/Evofem Biosciences, Inc.)
(PRNewsfoto/Evofem Biosciences, Inc.)

Date:

Friday, June 4, 2021

Time:

10:30 a.m. ET (7:30 a.m. PT)

Webcast:

https://wsw.com/webcast/jeff174/evfm/1851714

The presentation will be webcast live and archived for 30 days thereafter.

About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company launched its first FDA-approved commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate), in the United States in September 2020. The Company is evaluating lead product candidate EVO100 for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women in the ongoing Phase 3 clinical trial, 'EVOGUARD.' For more information, please visit evofem.com.

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-jefferies-virtual-healthcare-conference-2021-301302444.html

SOURCE Evofem Biosciences, Inc.